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Gentamicin (G) and vancomycin (V) concentrations in drainage fluids obtained from patients during the first 24 hours after
implantation of antibiotic-loaded polymethylmethacrylate (PMMA) spacers in two-stage revision of infected total hip arthroplasty
were studied.The inhibitory activity of drainage fluids against differentmultiresistant clinical isolates was investigated as well. Seven
hips were treated by implantation of industrial G-loaded spacers. Vancomycin was added by manually mixing with PMMA bone
cement. Serum and drainage fluid samples were collected 1, 4, and 24 hours after spacer implantation. Antibiotics concentrations
and drains bactericidal titer of combination were determined against multiresistant staphylococcal strains. The release of G and
V from PMMA cement at the site of infection was prompt and effective. Serum levels were below the limit of detection. The local
release kinetics of G and V from PMMA cement was similar, exerting a pronounced, combined inhibitory effect in the implant
site. The inhibitory activity of drainage fluids showed substantial intersubject variability related to antibiotic concentrations and
differed according to the pathogens tested. Gentamicin and vancomycin were released from temporary hip spacers at bactericidal
concentrations, and their use in combination exerted strong inhibition against methicillin-resistant S. aureus and Coagulase
Negative Staphylococci strains.
1. Introduction
Polymethylmethacrylate (PMMA) cements preloaded with
antibiotics, mainly gentamicin (G), are used in some cases for
prophylaxis but especially for the surgical revision of pros-
thetic infections [1]. Frequent microorganisms isolated from
joint fluid or periprosthetic tissue are the Coagulase Negative
Staphylococci (CoNS), S. aureus and most commonly S.
epidermidis, and Streptococcus haemolyticus [2]. Currently,
the routinely used methods of culturing are likely to detect in
most, not all, cases the pathogens possibly involved in infec-
tion of a total hip arthroplasty (THA) [3]. Some difficult-to-
treat bacteria, such asmethicillin-resistant S. aureus (MRSA),
methicillin-resistant CoNS, enterococci, and Pseudomonas
aeruginosa present much greater failure risks. In a number
of cases S. aureus infection is the significant factor associated
with treatment failure, along with retained prosthesis and
treatment with inappropriate antibiotics [4]. A two-stage
revision of an infected arthroplasty with antibiotic-loaded
spacer implantation is considered an effective procedure for
these infections [2, 5].
Because of the increasing resistance of staphylococci to
gentamicin, surgeons commonly add antibiotics to bone
cement directly in the operating room according to microor-
ganism susceptibility. Vancomycin (V) is frequently utilized
because of its antimicrobial activity against MRSA and other
Gram-positive cocci and anaerobes, such as propionibacteria.
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This drug delivery system offers the advantage of local
release of high antibiotic concentrations, which considerably
exceed those obtained after systemic administration.
Combining two antibiotics in bone cement is common in
clinical practice. As the effect of mixing on elution character-
istics is still debated, only limited data are available on antibi-
otic release in vivo from prosthetic devices after implantation
[6–8], as well as after removal [9, 10]. Moreover, the wide
variability of the results makes it difficult to compare studies
and draw general conclusions.The properties of various bone
cements, the preparation, type and concentrations of different
antibiotics mixed with PMMA, the pathogens involved, and
patient characteristics are all factors contributing to the
clinical outcome and should be taken into account in the
final evaluation of treatments. We previously observed that
gentamicin and vancomycin were still present in explanted
spacers after 3 to 9months of permanence in situ; the residual
drug concentrations showed great variability [11].
Open questions are related to the concentrations of
antibiotics at the implantation site and to the duration of their
effective inhibitory activity.
The aims of the present study were (1) to measure the
concentrations of antibiotics present at the infection site in
the first few hours after implanting the hip preformed spacer;
(2) to evaluate if antibiotics are released in large amounts
consistent with the results of in vitro experiments; (3) and
finally to assess the antimicrobial activity of drainage fluids
against multiresistant microorganisms.
To the best of our knowledge, this is the first study which
details the antibiotic release from industrially manufactured
temporary spacers in infected hip arthroplasties.
2. Materials and Methods
From January 2004 to September 2005, 7 patients who
received preformed spacers for two-stage revision of a THA
were investigated. There were 4 male and 3 female patients,
whose age ranged between 51 and 78 years (average, 65.6
years) at the time of implantation. All THAs were performed
for osteoarthritis. Diagnosis was suspected on the basis of
clinical findings (persistent pain or recurrence 3–5 years
later, presence of a secreting fistula, swelling, erythema, local
warmth, and restricted range of motion) and of the ESR and
the CRP (which were always elevated) [12]. Standard X-ray
and scintigraphy with labeled leukocytes were performed in
all the patients [12–16]. Intraoperative biopsy of bone and
soft tissue was always carried out, and the Feldman and the
Athanasou criteria were used to define infection [17, 18]. The
management of infection included removal of the prosthesis
and insertion of a preformed antibiotic-loadedPMMAspacer
(Tecres S.p.A., Sommacampagna, Verona, Italy).
The hip preformed spacer, Spacer-G, has a structure in
stainless steel AISI 316ESR, and it is available in 3 different
diameters of the head (46, 54, and 60mm) and 2 lengths of
the stem (153 and 270mm). The gentamicin concentration is
2.5%. Currently, it is also available with flat rod (Flat Stem
Spacer-G) and industrially supplementedwith vancomycin at
concentration of 2.5% (Vancogenx Hip-Space).
Removal of the septic implant was followed by a thorough
periprosthetic debridement and implantation of the spacer
(Figures 1(a) and 1(b)). A vancomycin-loaded bone cement
was prepared manually by mixing 40 g of powered cement
PMMA polymer (Cemex, Tecres S.p.A., Sommacampagna,
Verona, Italy) and 1 g of vancomycin (Vancocin, Eli Lilly,
Milan, Italy). Finally, 35mL of liquid MMA monomer was
added and carefullymixedwith a spatula [11, 19]. Vancomycin
addition to hip spacers was obtained by filling with the
cement mixture 17-18 holes (10–12mm diameter, 2-3mm
depth) which were drilled in the surface of the Spacer-
G immediately before implantation (Figure 2). Each device
received 6-7 g of cement, corresponding to 150–170mg of
vancomycin, respectively. Vancomycin (Vancocin, 1 g, twice
daily) was also administered intravenously to 1 patient as
control case.
Two- to 3-week standard parenteral antibiotics adminis-
tration (cefazolin, Cefamezin, Pfizer Italia, Roma, Italy; 1 g
four times a day; i.v.) was given to the remaining patients,
followed by oral therapy, according to infectious disease
consultant, for an overall treatment of 6 weeks. Outpa-
tients clinical evaluation was arranged monthly, including
laboratory tests (WBC, ESR, and CRP) and radiographic
examination (anteroposterior and lateral views). Due to an
immediate pain relief after surgery, a standard physiotherapy
regimen including continuous passive motion was carried
out. Partial to total weight bearing on the operated leg using
two crutches was allowed until reimplantation.
In all the cases, eradication of infection was obtained,
and the second surgical step, including the removal of the
spacer and the application of a new THA, was performed
successfully when patient’s laboratory indices became normal
and when bone scintigraphy with labeled leukocytes was
negative for infection. In the postoperative period, parenteral
antibiotic treatment was administered for 6 weeks in all the
patients according to the pathogen identification or with
broad-spectrum antibiotics in case of lack identification (2
patients) starting from day 3rd with the exception of the
patients control case which started preoperatively.
Fluids drainage and serum samples to 1, 4, and 24 hours
after the first surgical step were collected in all cases. Con-
centrations of gentamicin and vancomycin were determined
in parallel by Fluorescence Polarisation Immunoassay (TDx,
Abbott). The lowest measurable level of drug concentration
was defined as that which could be distinguished from 0
with 95% confidence; this was determined as 0.27mg/L
for G and 2.0mg/L for V [11]. The antibacterial activity
determination was also done on different orthopaedic strains
isolates with differing degrees of resistance. Bacterial strains
were multiresistant clinical isolates obtained from Intensive
Care Unit in patients, kindly provided by the Microbiology
Department of the local university (Table 1).
The MICs of gentamicin, vancomycin, and their combi-
nations were determined using the broth microdilution tech-
nique as recommended by the CLSI (Clinical and Laboratory
Standards Institute) guidelines [20]. Resistance of the staphy-
lococcus strains was determined according to international
standard methods [21]. Resistance to gentamicin was defined
by MIC
90
> 32mg/L; gentamicin-intermediate resistance by
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Figure 1: PreoperativeX-ray of a total hip arthroplasty complicated by chronic infection (a). Radiograph obtained after removal of the infected
prosthesis and implantation of an industrially manufactured spacer (b).
Figure 2: Image of the preformed gentamicin-loaded cement spacer
after surgical addition of vancomycin using the “surface drill hole”
technique.
MIC
90
= 8.0mg/L, and resistance to vancomycin by MIC
90
>
4.0mg/L for the strains tested. Synergy testingwas performed
in duplicate using the chequerboard method in microtiter
plates withMueller-Hinton Broth (MHB, Difco). Gentamicin
and vancomycin were diluted in MHB and tested at different
twofold concentrations (from 0.3 to 20.0mg/L) against all
strains (final inoculum 1 × 105 CFU/mL). The fractional
inhibitory concentration index (FICI) was calculated and
interpreted for each strain [22]: the FICI was defined as
synergistic if the values were <0.5, indifferent or additive if
the values were from 0.5 to 4.0, and antagonistic if the values
were >4.0 [23] (Table 1).
Table 1: In vitro activity of gentamicin and vancomycin in combina-
tion against multiresistant clinical isolates.
Vancomycin + gentamicin
Strain MIC (mg/L)
Vancomycin Gentamicin FICI
S. aureus 2.5 10 0.15
S. epidermidis 2.5 3750 1.00
S. haemolyticus 1.25 3750 1.00
S. haemolyticus
Methicillin-resistant 1.25 3750 1.00
S. epidermidis
Methicillin-resistant 2.5 58.6 0.50
S. hominisMethicillin-resistant 1.25 15 1.02
E. coli 156.25 5.0 0.25
P. aeruginosa 1250 5.0 0.12
Twofold serial dilutions of patient drainages were pre-
pared in microtiter plates using Mueller-Hinton Broth as
diluent.The final volumewas 0.1mL in eachwell, and 0.01mL
of each strain from overnight cultures was added to each
well, including a growth control well, without drainage; an
absolute control (MHB only) was also provided. Microplates
were incubated for at least 18 h at 37∘C. Subcultures for the
99.9% bactericidal endpoints were performed in Brain Heart
Agar.The drainage fluid bactericidal titer (DBT) is a measure
of the drainage fluid killing capacity against the infecting
organism; it was determined as the highest fluid dilution
achieving 99.9% bacterial killing. The score 3, corresponding
to a 1/8 dilution, was considered the lowest effective titer for
orthopaedic infections [24, 25].
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Table 2: Bactericidal titer of drainage fluids collected from 7 patients within the first 24 hours of spacer implantation against multiresistant
clinical isolates.
Strain
DBT
PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7
1 h 24 h 1 h 24 h 1 h 24 h 1 h 24 h 1 h 24 h 1 h 24 h 1 h 24 h
S. aureus 6 9 9 9 6 5 5 5 3 2 3 4 6 4
S. epidermidis 3.3 6 5 3 4 4 4 4 0 1 4 4 5 3
S. haemolyticus 3.3 6 6 7 4 3 4 4 0 1 3 3 4 3
S. haemolyticusMethicillin-resistant 3 5 4 3 4 4 4 3 0 0 4 5 4 3
S. epidermidisMethicillin-resistant 3.3 6 4.3 2 4 3 4 4 0 0 7 7 4 3
S. hominisMethicillin-resistant 5 8 7 5 5 5 4 5 0 1 5 5 6 4
E. coli 6 9 5 6 4 4 4 5 2 1 5 3 6 4
P. aeruginosa 4 6 5 5 4 4 3 4 0 0 5 6 5 3
3. Results
The release of gentamicin from PMMA cement at the site
of infection showed high local concentrations (range 15.0–
90.0mg/L) in the first few hours after spacer implanta-
tion. Gentamicin serum levels were invariably very low
(<0.2–1.0mg/L). The local administration of vancomycin
(2.5%) produced high concentrations (ranging from 13.8 to
40.0mg/L) at the implant site in the first hour.This behaviour
persisted 4 and 24 hours after spacer implantation. The
corresponding serum levels were below the threshold for
systemic toxicity (<10mg/L for gentamicin and <40mg/L
for vancomycin); however, vancomycin attained therapeutic
concentrations after parenteral administration, but again
below systemic toxicity limits.
The levels of each antibiotic in drainage fluids were
all above the concentrations needed to inhibit susceptible
bacteria, and their use in combination appears to be capable
of exerting pronounced antimicrobial activity and also a syn-
ergistic effect against some multiresistant microorganisms.
The DBT score was high (above 3) in the first few
hours after drug release (1/8 titer) for all strains tested;
an effective titer was maintained for almost 24 hours. The
same drainage fluid presented different inhibitory capacities
against various multiresistant strains. For example, patient
n. 1 exhibited good inhibitory activity (DBT = 6) against
E. coli, S. aureus, and lower inhibitory activity (DBT = 4)
against P. aeruginosa; patient n. 6 had good inhibitory activity
(DBT = 7) against S. epidermidis Methicillin-resistant and
lower inhibitory activity (DBT = 3-4) against S. aureus, S.
haemolyticus (2 strains), and S. epidermidis. Patient n. 7
showed good inhibitory activity (DBT= 6) against S. hominis,
S. aureus and lower inhibitory activity (DBT = 4) against
S. haemolyticus (2 strains) and S. epidermidis. Moreover,
the fluid maintained high activity against the Gram-negative
strains E. coli and P. aeruginosa (Table 2).
The fluid collected from patient who also received local
and systemic vancomycin (control case) was inhibitory
against the majority of tested strains and higher against S.
aureus during the first 24 hours after implantation.
Depending on the different antibiotic concentrations in
the microtiter plates and microorganisms tested, the samples
inhibitory activity was variable. DBT scores indicated good
inhibitory activity after 24 hours when G and V in com-
bination were present at adequate concentrations (in these
conditions, ≥8mg/L and ≥2mg/L, resp.) and when the G : V
ratio was at least 2 : 1.
Pain relief after application of the spacer was obtained
in all cases, and partial weight bearing with crutches was
allowed. There were no general or local complications
(dislocation, breakage, and loosening of the spacer). No
adverse drug reaction (hypersensitivity, erythema, edema,
etc.) attributable to gentamicin or vancomycin was reported
after local and systemic drug administration.
4. Discussion
Periprosthetic hip infection following THA is a serious
problem, and different treatment options related to the type of
infection are available. In two-stage revision procedure, tem-
porary spacers made of antibiotic-loaded PMMA represent a
viable option for a chronically infected THA, allowing local
antibiotic delivery and maintaining soft tissue length, which
facilitates reimplantation [10, 26].
Industrially preformed spacer has some advantages such
as ease of use, high availability in sizes, and excellent acetab-
ular bone quality at the time of revision [26]. With the use
of this specific device, many authors have reported good
eradication rate ranging from 80 to 93.3% [26–29]. Industrial
production ensures procedure standardization eliminating
the time necessary to intraoperative manufacturing [26].
However, spacer-related complications, such as dislocations
and fractures, have been described as well, ranging from 3.3
to 17% [26–29].
In this study, the release of gentamicin and vancomycin
in the first 24 hours after implantation of hip preformed
spacers was evaluated. Gentamicin and vancomycin concen-
trations were very high and strongly bactericidal in suction
drainage fluid samples one hour after spacer implantation and
remained high for at least 24 hours. These results confirm
the findings of Anagnostakos et al., who firstly reported high
concentrations of antibiotics in drainage fluids in the first few
days after implantation of beads or spacer [10]. In addition,we
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observed different inhibitory capacities exerted by the same
drainage fluid against several multiresistant clinical isolates.
Gentamicin and vancomycin concentrations determined
singly in drainage fluids in the first 24 hours were very
high and stable but not inhibitory against multiresistant
strains. However, gentamicin and vancomycin act sinergis-
tically against several multiresistant staphylococcal strains,
as shown by the FICI and the DBT scores. The therapeutic
rationale for combining G and V depends on the suscepti-
bility of the infecting pathogens, and vancomycin use should
be limited to infections likely to be caused by more resistant
Gram-positive bacteria, such as S. epidermidis, methicillin-
resistant staphylococci, CoNS, or enterococci [30, 31]. Cefa-
zolin, not dosed, could contribute to antimicrobial activity
of drainage fluids; it is effective mainly against susceptible
strains, S. aureus (9A28) and S. aureus (3A10), and ineffective
against the multiresistant strains as confirmed recently [32].
In our patients, gentamicin and vancomycin serum levels
were below the threshold for systemic toxicity, and no signs
of nephrotoxicity or local cytotoxic effects were observed.
These data confirm the safety aspects of local drug delivery
and the good tolerability of systemic and local levels. A
low frequency of adverse reactions has been reported with
antibiotic-containing spacers [10], though damage to the
kidney and increased mortality has also been reported. In
a systematic review including 10 observational studies, Luu
et al. [33] showed an average incidence of acute kidney
injury of 4.8% using antibiotic spacer. Berend at al. [34]
studiedmortality rates associatedwith two-stage treatment of
infectedTHA in 202 patients undergoing two-stage treatment
for infection, including removal of all implants and foreign
material with implantation of an antibiotic-loaded cement
spacer in the first stage followed by intravenous culture-
specific antibiotics for a minimum of 6 weeks. Fourteen
patients (7%) died before reimplantation, and two were not
candidates because of medical comorbidities. The 90-day
mortality rate after the first-stage debridement was 4%.
5. Conclusions
The results of the present investigation provide data on
the release of gentamicin and vancomycin from preformed
antibiotic cement spacers in the first 24 hours after implan-
tation, supporting the potential clinical efficacy of the
gentamicin-vancomycin combination in two-stage manage-
ment of infected THA. Preformed spacers loaded with G
and V are a safe method of delivering high concentration
of antibiotics to the infection site with low serum levels,
achieving effective release kinetics. The use of industrially
preformed spacers should be advantageous in terms of
standardization of the device characteristics, uniform cement
mix with antibiotics, and reproducible drug release.
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